{"denoms":[{"counts":[{"groupId":"BG000","value":"231"},{"groupId":"BG001","value":"229"},{"groupId":"BG002","value":"460"}],"units":"Participants"}],"groups":[{"description":"Beginning between day 100-110, patients receive oral lenalidomide once daily - 10 mg/day for the first 3 months, then if tolerated, 15 mg/day.","id":"BG000","title":"Lenalidomide Maintenance"},{"description":"Beginning between day 100-110, patients receive oral placebo once daily - 10 mg/day for the first 3 months, then if tolerated, 15 mg/day.\n\n(closed as of 12/17/09)","id":"BG001","title":"Placebo Maintenance"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"29","upperLimit":"71","value":"59"},{"groupId":"BG001","lowerLimit":"40","upperLimit":"71","value":"58"},{"groupId":"BG002","lowerLimit":"29","upperLimit":"71","value":"59"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"110"},{"groupId":"BG001","value":"100"},{"groupId":"BG002","value":"210"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"121"},{"groupId":"BG001","value":"129"},{"groupId":"BG002","value":"250"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"231"},{"groupId":"BG001","value":"229"},{"groupId":"BG002","value":"460"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"105"}]}],"title":"> 2.5 mg/liter"},{"categories":[{"measurements":[{"groupId":"BG000","value":"170"},{"groupId":"BG001","value":"163"},{"groupId":"BG002","value":"333"}]}],"title":"<= 2.5 mg/liter"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"22"}]}],"title":"Missing data"}],"paramType":"NUMBER","title":"Beta 2 microglobulin at registration","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"102"},{"groupId":"BG001","value":"103"},{"groupId":"BG002","value":"205"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"129"},{"groupId":"BG001","value":"126"},{"groupId":"BG002","value":"255"}]}],"title":"No"}],"paramType":"NUMBER","title":"Prior use of thalidomide during induction","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"79"},{"groupId":"BG001","value":"81"},{"groupId":"BG002","value":"160"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"152"},{"groupId":"BG001","value":"148"},{"groupId":"BG002","value":"300"}]}],"title":"No"}],"paramType":"NUMBER","title":"Prior use of lenalidomide during induction therapy","unitOfMeasure":"participants"}]}